The burden of infant meningococcal disease in the United States

Journal of the Pediatric Infectious Diseases Society

Volumn 1, Issue 1, 2012, Pages 64-73

  Judelsohn, R ^a   Marshall, G S ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYW 135; ANTIBIOTIC AGENT; MCV4 CRM; MCV4 D; MENHIBRIX; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

HUMAN; INFANT DISEASE; INFECTION CONTROL; INFECTION RISK; MENINGOCOCCOSIS; META ANALYSIS (TOPIC); MORTALITY; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; UNITED STATES; VACCINATION;

EID: 84894952017     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/pir003     Document Type: Review

References (62)

1. Sáez-Llorens X, McCracken GH Jr. Bacterial meningitis in children. Lancet 2003; 361:2139-48.
2. Centers for Disease Control and Prevention. Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children-United States, 1998-2000. MMWR Morb Mortal Wkly Rep 2002; 51:234-7.
3. Pilishvili T, Lexau C, Farley MM, et al. Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41.
4. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54:1-21.
5. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. MMWR Morb Mortal Wkly Rep 2007; 56:794-5.
6. Centers for Disease Control and Prevention (CDC). Recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2-10 years at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2007; 56:1265-6.
7. Centers for Disease Control and Prevention (CDC). Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb Mortal Wkly Rep 2009; 58:1042-3.
8. Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1018-9.
9. Centers for Disease Control and Prevention. Updated recommendations for use of meningococcal conjugate vaccines-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011; 60:72-6.
10. Centers for Disease Control and Prevention (CDC). Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2011; 60:1391-2.
11. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184-91.
12. Centers for Disease Control and Prevention (CDC). Summary of notifiable diseases-United States, 2009. MMWR Morb Mortal Wkly Rep 2011; 58:1-100.
13. McNabb SJ, Jajosky RA, Hall-Baker PA, et al. Summary of notifiable diseases-United States, 2006. MMWR Morb MortalWkIy Rep 2008; 55:1-92.
14. Centers for Disease Control and Prevention (CDC). Final 2010 reports of nationally notifiable infectious diseases. MMWR Morb Mortal Wkly Rep 2011; 60:1088-115.
15. Harrison LH, Pelton SI, Wilder-Smith A, et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 2011; 29:3363-71.
16. Centers for Disease Control and Prevention (CDC). Meningococcal disease. In: Atkinson W, Wolfe S, Hamborsky J, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 12th ed. Washington, DC: Public Health Foundation, 2011:193-203.
17. Dunlop KA, Coyle P, Mitchell S, et al. Molecular testing of respiratory swabs aids early recognition of meningococcal disease in children. Diagn Microbiol Infect Dis 2011; 70:427-34.
18. Sacchi CT, Fukasawa LO, Goncalves MG, et al. Incorporation of RT-PCR into routine public health surveillance for meningococcal meningitis in São Paulo State, Brazil. In: IPNC 2010 17th International Pathogenic Neisseria Conference program and abstract guide [abstract P042]. Alberta, Canada: International Pathogenic Neisseria Conference, 2010:98.
19. Gray S, Campbell H, Marsh J, et al. The epidemiology and surveillance of meningococcal disease in England and Wales. In: IPNC 2010 17th International Pathogenic Neisseria Conference program and abstract guide [abstract P041]. Alberta, Canada: International Pathogenic Neisseria Conference, 2010:98.
20. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344:1378-88.
21. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969; 129:1307-26.
22. Trotter C, Borrow R, Andrews N, Miller E. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine 2003; 21:1094-98.
23. Jaspan HB, Lawn SD, Safrit JT, Bekker LG. The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents. AIDS 2006; 20:483-94.
24. Brouwer MC, Read RC, van de Beek D. Host genetics and outcome in meningococcal disease: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:262-74.
25. Wright V, Hibberd M, Levin M. Genetic polymorphisms in host response to meningococcal infection: the role of susceptibility and severity genes. Vaccine 2009; 27(Suppl 2):B90-102.
26. Ip WK, Takahashi K, Ezekowitz RA, Stuart LM. Mannose-binding lectin and innate immunity. Immunol Rev 2009; 230:9-21.
27. Faber J, Schuessler T, Finn A, et al. Age-dependent association of human mannosebinding lectin mutations with susceptibility to invasive meningococcal disease in childhood. Pediatr Infect Dis J 2007; 26:243-46.
28. Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J 1997; 16:979-83.
29. Christensen H, May M, Bowen L, Hickman M, Trotter C. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:853-61.
30. de GreeffSC, de Melker HE, Schouls LM, Spanjaard L, van Deuren M. Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: a prospective epidemiology study on 752 patients in the Netherlands, 2003-2005. Eur J Clin Microbiol Infect Dis 2008; 27:985-92.
31. Hameed R, Riordan FA. Meningococcal disease presenting as bronchiolitis. J Infect Dis 2002; 44:94-5.
32. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet 2006; 67:397-403.
33. Kaplan SL, SchutzeGE, Leake JA, et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics 2006; 118:e979-84.
34. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369:2196-2210.
35. Centers for Disease Control and Prevention (CDC). Four-month-old female with gangrene of the feet and hands due to meningococcemia. http://www.vaccineinformation.org/menin/photos.asp. Accessed 1 August 2011.
36. MacNeil J. Epidemiology of meningococcal disease in infants and young children. Meeting of the Advisory Committee on Immunization Practices. 21-22 October 2009. Available at: http://www.cdc.gov/vaccines/recs/acip/downloads/min-archive/min-oct09.pdf. 91-94.
37. GranoffDM, Gilsdorf JR. Neisseria meningitidis (meningococcus). In: Kliegman RM, Stanton BF, Geme JS, Schor NF, Behrman RE, eds. Nelson Textbook of Pediatrics. 19th ed. Philadelphia: WB Saunders Co, 2011:929-35.
38. Lowe KG, Boyce JM. Rehabilitation of a child with meningococcal septicemia and quadrilateral limb loss: a case report. Arch Phys Med Rehabil 2004; 85:1354-57.
39. Allport T, Read L, Nadel S, LevinM. Critical illness and amputation in meningococcal septicemia: is life worth saving? Pediatrics 2008; 122:629-32.
40. Lucaya J, Garel L, Piqueras J. Clinical quiz. Sequelae of meningococcal sepsis. Pediatr Radiol 2004; 34:441-2.
41. Bedford H, de Louvois J, Halket S, Peckham C, Hurley R, Harvey D. Meningitis in infancy in England and Wales: follow up at age 5 years. BMJ 2001; 323:533-6.
42. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis 1998; 26:1159-64.
43. Judge D, Nadel S, Vergnaud S, Garralda ME. Psychiatric adjustment following meningococcal disease treated on a PICU. Intensive Care Med 2002; 28:648-50.
44. Ehrlich TR, von Rosenstiel IA, Grootenhuis MA, Gerrits AI, Bos AP. Long-term psychological distress in parents of child survivors of severe meningococcal disease. Pediatr Rehabil 2005; 8:220-4.
45. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27(Suppl 2):B51-63.
46. Toropainen M, Vainio A, Saarinen L, Kuusi M, Kayhty H, Virolainen A. Epidemiology of invasive meningococcal disease in Finland, 1995-2010. In: EMGM 2011 abstract book [abstract P009]. Ljubljana, Slovenia: The European Meningococcal Disease Society, 2011:51.
47. Centers for Disease Control and Prevention (CDC). Active bacterial core surveillance report, emerging infections program network, Neisseria meningitidis, 2009. http://www.cdc.gov/abcs/reports-findings/surv-reports.html. Accessed 31 July 2011.
48. Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989-1991. MMWR Surveill Summ 1993; 42:21-30.
49. Harrison LH, Shutt KA, Schmink SE, et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era-United States, 2000-2005. J Infect Dis 2010; 201:1208-24.
50. Memish ZA, Goubeaud A, Bröker M, Malerczyk C, Shibl AM. Invasive meningococcal disease and travel. J Infect Public Health 2010; 3:143-51.
51. McMullan B. An infant with meningococcal arthritis of the hip. J Paediatr Child Health 2009; 45:762-3.
52. Bolt P, Britto J, Nadel S, Levin M. Meningococcal disease due to W135: fresh public health concerns. Arch Dis Child 2001; 84:90-1.
53. Menactra [prescribing information]. Swiftwater, PA: SanofiPasteur, Inc., 2011.
54. Menveo [prescribing information]. Cambridge, MA: Novartis Vaccines and Diagnostics, Inc., 2011.
55. Menomune [prescribing information]. Swiftwater, PA: SanofiPasteur, Inc., 2009.
56. Perrett KP, Snape MD, Ford KJ, et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J 2009; 28:186-93.
57. Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008; 299:173-84.
58. Bryant KA, Marshall GS, Marchant CD, et al. Immunogenicity and safety of H. influenzae type b-N. meningitidis C/Y conjugate vaccine in infants. Pediatrics 2011; 127:e1375-85.
59. Marchant CD, Miller JM, Marshall GS, et al. HibMenCY-TT 005 Study Group. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2010; 29:48-52.
60. Marshall GS, Marchant CD, Blatter M, et al. Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age. Pediatr Infect Dis J 2010; 29:469-71.
61. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006; 103:10834-9.
62. Toneatto D, Oster P, Deboer AC, et al. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Hum Vaccin 2011; 7:781-91.